sábado, 28 de abril de 2012

Stroke risk high when anti-clotting drugs stopped / American Heart Association

Stroke risk high when anti-clotting drugs stopped / American Heart Association

Stroke risk high when anti-clotting drugs stopped

Study Highlights:
  • Patients with irregular heartbeats who take anti-clotting medications are at high risk of stroke or blood clot whenever the drugs are stopped.
  • The risks are similar whether patients are taking warfarin or a newer anti-clotting drug rivaroxaban.
EMBARGOED UNTIL Noon CT/1 pm ET, Wednesday, April 25
DALLAS, April 25, 2012 — Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke External link or blood clotting within a month, according to new research presented at the American Heart Association’s Emerging Science Series webinar.
Patients with certain types of atrial fibrillation External link, or irregular heartbeat, take these drugs to reduce the risks of clots that could lead to a stroke. Sometimes they are instructed to stop taking the medication temporarily before surgery or permanently because of side effects.
“No matter what drug they are on, patients who need anticoagulation revert back to their intrinsic risk of stroke and embolism after discontinuation, so it shouldn’t be done lightly,” said Manesh Patel, M.D., lead author and assistant professor of medicine at the Duke University School of Medicine. “Unfortunately, it’s unclear how to provide optimal anti-coagulation coverage during periods of transition.”
Researchers analyzed data from a clinical trial known as ROCKET AF, finding the risk is similar whether patients are taking the drug warfarin or the newer anticoagulant rivaroxaban. Rivaroxaban is taken once daily and doesn’t require the frequent monitoring of warfarin, which requires frequent dose-adjustment.
In ROCKET AF, rivaroxaban was found to be as effective as warfarin in preventing stroke and blood clots in more than 14,000 patients with atrial fibrillation. Patients also had no greater risk of bleeding. However, concerns persisted about possible increased rates of stroke and blood clots after discontinuing rivaroxaban, which led to a warning in the prescribing information.
Because of these concerns, the researchers analyzed strokes and blood clots that occurred following temporary interruptions, and between 3 and 30 days after early drug discontinuation or the transition to warfarin at the study’s end.  
Strokes and blood clots occurred:
  • At similar rates with both drugs after a temporary interruption – 6.20/100 patient-years for those on rivaroxaban vs. 5.05/100 patient-years for those taking warfarin;
  • At similar rates in both drugs after permanently stopping the medicines – 25.60/100 patient-years for people taking rivaroxaban (vs. 23.38/100 patient-years for those on warfarin;
  • More often in the transition from rivaroxaban to open label therapy (6.42/100 patient-years) vs. warfarin (1.73/100 patient-years). However, the risk seems to be high only for stroke. There was no difference between the drugs when investigators evaluated all blood clot-related events (including strokes, heart attack and vascular death) within 30 days of stopping medication.
Co-authors are: Anne S. Hellkamp, M.S.; Yuliya Lokhnygina, Ph.D.; Jonathan P. Piccini, M.D.; Guohua Pan, Ph.D.; Daniel E. Singer, M.D.; Werner Hacke, M.D., Ph.D.; Günter Breithardt, M.D.: Jonathan L. Halperin, M.D.; Graeme J. Hankey, M.D.; Richard C. Becker, M.D.; Christopher C. Nessel, M.D.; Scott D. Berkowitz, M.D.; Robert M. Califf, M.D.; Keith A.A. Fox, M.B., Ch.B.; and Kenneth W. Mahaffey, M.D. Disclosures are on the abstract.
The research is funded by the Duke Clinical Research Institute, Johnson & Johnson, and Bayer HealthCare AG.
More information about atrial fibrillation is at heart.org/afib External link. For more about stroke visit strokeassociation.org External link.
Statements and conclusions of study authors published in American Heart Association scientific journals or presented at American Heart Association conferences are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding External link.
NR12 – 1062 (ESS/Patel)
Additional resources, including multimedia, are available in the right column.
For Media Inquiries: (214) 706-1173
Maggie Francis: (214) 706-1382; maggie.francis@heart.org
Carrie Thacker: (214) 706-1665; carrie.thacker@heart.org
Julie Del Barto (broadcast): (214) 706-1330; julie.delbarto@heart.org
For Public Inquiries: (800) AHA-USA1 (242-8721)

No hay comentarios:

Publicar un comentario